We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kite Pharma Completes Filing for CAR-T Therapy with FDA
Read MoreHide Full Article
Kite Pharma, Inc. announced that it has completed the filing of a rolling submission of the Biologics License Application (BLA) for its lead pipeline candidate, axicabtagene ciloleucel to the FDA.
We note that axicabtagene ciloleucel is Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy.
The BLA is for the treatment for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who are ineligible for autologous stem cell transplant (ASCT).
So far this year, Kite Pharma’s shares are up 74.7%. This compares favorably with the 3.6% increase registered by the Zacks classified Biomed/Genetics industry during this period.
Kite Pharma is looking to get axicabtagene ciloleucel approved for a broader label of aggressive NHL including drefractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL) indications, based on the primary analysis of ZUMA-1 study. DLBCL, TFL and PMBCL are all types of aggressive NHL.
Last month, Kite Pharma announced positive top-line six-month results from the primary analysis of 101 patients in the ZUMA-1 study. The study met the primary endpoint. At the end of six months, after axicabtagene ciloleucel treatment, 41% of the patients achieved a response, including 36% achieving a complete response. The key takeaway from the data was the durability of response compared to data presented for the third month. The solid efficacy profile demonstrated by the study furthers the likelihood of FDA approval of the drug. In Sep 2016, the company had announced encouraging top-line results from the phase II part of ZUMA-1 study.
Axicabtagene ciloleucel is expected to be approved and launched in 2017. In Europe, regulatory applications are expected to be filed in the second half of this year.
We note that the development of CAR T cell therapies has been attracting a lot of attention lately with several companies eyeing this field. Juno Therapeutics Inc. is also working on developing therapies utilizing the CAR T cell technology. In fact, interest in immunotherapy is building up fast. The basic concept of cancer immunotherapy or immuno-oncology is to utilize certain parts of the immune system to fight the disease. This can be done by stimulating the immune system to attack cancer cells or by introducing immune system components into the body.
Merck & Co., Inc.’s (MRK - Free Report) anti-PD-1 therapy, Keytruda, is being studied for more than 30 types of cancers. Amgen Inc.’s (AMGN - Free Report) Blincyto, a BiTE antibody, gained earlier-than-expected FDA approval in Dec 2014. Blincyto has the potential to be developed for other hematologic malignancies as well.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007?
Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Kite Pharma Completes Filing for CAR-T Therapy with FDA
Kite Pharma, Inc. announced that it has completed the filing of a rolling submission of the Biologics License Application (BLA) for its lead pipeline candidate, axicabtagene ciloleucel to the FDA.
We note that axicabtagene ciloleucel is Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy.
The BLA is for the treatment for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who are ineligible for autologous stem cell transplant (ASCT).
So far this year, Kite Pharma’s shares are up 74.7%. This compares favorably with the 3.6% increase registered by the Zacks classified Biomed/Genetics industry during this period.
Kite Pharma is looking to get axicabtagene ciloleucel approved for a broader label of aggressive NHL including drefractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL) indications, based on the primary analysis of ZUMA-1 study. DLBCL, TFL and PMBCL are all types of aggressive NHL.
Last month, Kite Pharma announced positive top-line six-month results from the primary analysis of 101 patients in the ZUMA-1 study. The study met the primary endpoint. At the end of six months, after axicabtagene ciloleucel treatment, 41% of the patients achieved a response, including 36% achieving a complete response. The key takeaway from the data was the durability of response compared to data presented for the third month. The solid efficacy profile demonstrated by the study furthers the likelihood of FDA approval of the drug. In Sep 2016, the company had announced encouraging top-line results from the phase II part of ZUMA-1 study.
Axicabtagene ciloleucel is expected to be approved and launched in 2017. In Europe, regulatory applications are expected to be filed in the second half of this year.
We note that the development of CAR T cell therapies has been attracting a lot of attention lately with several companies eyeing this field. Juno Therapeutics Inc. is also working on developing therapies utilizing the CAR T cell technology. In fact, interest in immunotherapy is building up fast. The basic concept of cancer immunotherapy or immuno-oncology is to utilize certain parts of the immune system to fight the disease. This can be done by stimulating the immune system to attack cancer cells or by introducing immune system components into the body.
Merck & Co., Inc.’s (MRK - Free Report) anti-PD-1 therapy, Keytruda, is being studied for more than 30 types of cancers. Amgen Inc.’s (AMGN - Free Report) Blincyto, a BiTE antibody, gained earlier-than-expected FDA approval in Dec 2014. Blincyto has the potential to be developed for other hematologic malignancies as well.
Kite Pharma carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007?
Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>